Pharmaceutical firm Shire has raised its guidance for full-year earnings, underlining its strong prospects as a standalone company after AbbVie officially dropped its $55 billion purchase of the group on Tuesday. 

Shire, which produces drugs to treat hyperactivity and rare diseases, posted a 60% jump in third-quarter earnings per share to $2.93 on revenue up nearly a third at $1.6 billion. 

It said it now expected to deliver earnings growth in the high 30% range for the full year, up from its expectations in July of growth in the low-to-mid 30% range. 

AbbVie walked away from the deal after the US Treasury department tightened its rules to curtail companies doing deals that would allow them to redomicile overseas to cut corporate tax rates. 

In its initial defence against a takeover, Shire had said it planned to double sales to $10 billion by 2020, $7 billion of which would come from its existing products and $3 billion from its pipeline. 

The group, which has been created through a series of deals, has $9 billion of firepower to make acquisitions, analysts said earlier this year.

That sum will be boosted by a break fee of $1.635 billion payable by AbbVie to Shire.